- A participant raised a rare variant of Angelman Syndrome caused by a deficiency in UBE1 (ubiquitin-activating enzyme) rather than the more common UBE3A (ubiquitin ligase) defect, prompting discussion on current gene-therapy approaches for this 1-in-250,000 condition.  
- Dale Bredesen’s metabolic strategy for preventing protein degradation to treat cognitive disorders was suggested as a complementary avenue worth exploring for the UBE1-deficiency case.